Is Mounjaro the same as Tirzepatide?

Yes — Tirzepatide is the active ingredient in Mounjaro, an Eli Lilly brand-name prescription product. The molecule is identical; the difference is the brand, the label, and the source. Vancouver Island Peptides supplies Tirzepatide as a research compound synthesized domestically in Vancouver, BC — not the branded pharmaceutical.

What is the difference between Tirzepatide and Ozempic?

Ozempic's active ingredient, Semaglutide, is a single GLP-1 agonist. Tirzepatide (the molecule in Mounjaro) is a dual GLP-1/GIP agonist, adding a second receptor pathway that supports insulin sensitivity and energy balance.

Can I buy Tirzepatide in Canada?

Yes. Vancouver Island Peptides supplies Tirzepatide as a research compound synthesized in Vancouver, BC, available in 10mg and 20mg vials. It ships Canada-wide in discreet packaging and is sold for research and personal wellness purposes only, not approved by Health Canada for human use.

Is Tirzepatide stronger than Semaglutide?

Tirzepatide's dual GLP-1/GIP mechanism has shown more pronounced metabolic effects than single-agonist Semaglutide in head-to-head clinical research. For the broadest mechanism, the triple agonist Retatrutide adds glucagon activation on top of both.

← Vancouver Island Peptides / Blog

GLP-1 Research Peptides — Comparison

Tirzepatide vs Mounjaro: Same Molecule, Different Source

July 8, 2026

This is the shortest comparison in the GLP-1 space, because there is almost nothing to compare: Tirzepatide is the active ingredient in Mounjaro. Same molecule. The difference is entirely about branding, labelling, and where it comes from — not chemistry.

Mounjaro Is the Brand. Tirzepatide Is the Compound.

Mounjaro is Eli Lilly's brand name for a prescription product. Its active ingredient is Tirzepatide, a dual GLP-1/GIP receptor agonist. When people search "Tirzepatide vs Mounjaro," they are effectively comparing the same substance sold two different ways:

Mounjaro — a Health Canada-approved prescription pharmaceutical, dispensed by a pharmacy, at pharmaceutical pricing
Tirzepatide (research compound) — the same molecule supplied for laboratory and personal wellness research, synthesized domestically by Vancouver Island Peptides in Vancouver, BC

How the Dual Agonist Works

Tirzepatide activates two receptors rather than one, which is what set it apart from the earlier single-agonist generation:

GLP-1 — appetite regulation, gastric emptying, insulin response (the same pathway Semaglutide / Ozempic uses)
GIP — enhances insulin sensitivity and energy balance, the second mechanism Semaglutide lacks

Where It Sits in the GLP-1 Family

Compound	Brand Name	Receptor Targets
Semaglutide	Ozempic / Wegovy	GLP-1
Tirzepatide	Mounjaro	GLP-1 + GIP
Retatrutide	(no brand — research only)	GLP-1 + GIP + Glucagon

Tirzepatide sits in the middle: more mechanism than Semaglutide, less than the triple agonist Retatrutide. In head-to-head clinical research, its dual pathway has produced more pronounced metabolic effects than Semaglutide alone.

Sourcing Tirzepatide in Canada

Vancouver Island Peptides supplies Tirzepatide as a domestic research compound — synthesized at our Vancouver, BC lab partner, HPLC-verified to >99% purity, available in 10mg and 20mg vials, and shipped Canada-wide in discreet packaging. It never crosses a border, so there is no customs seizure risk and no cold-chain uncertainty.

View Tirzepatide Canada

See also: Retatrutide vs Ozempic (Semaglutide) — the two compounds on either side of Tirzepatide.

All products are intended for research and personal wellness purposes only. Not for human consumption. Not approved by Health Canada. Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners (Eli Lilly and Novo Nordisk); Vancouver Island Peptides is not affiliated with, endorsed by, or sponsored by these companies, and does not sell their branded products. We supply generic research compounds only. Consult a qualified healthcare provider before use. Ships within Canada only.